NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Enhanced Cell Line Productivity Technology to be Introduced by Catalent Biologics at PEGS Europe
Nov 12, 2019
Catalent today announced that Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics will present at the upcoming annual PEGS Europe conference, which will be held at the Lisboa Congress Center, Lisbon, Portugal, on Nov. 18 – 22, 2019.
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Nov 5, 2019
Catalent today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.
Catalent Biologics Launches GPEx® Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity
Nov 4, 2019
Catalent, today announced the launch of its next-generation cell line development technology, GPEx® Boost.
Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
Sep 12, 2019
Catalent, today announced that professor David Schaffer has been appointed to the advisory board of the company’s biologics business.
Flexible Filling And Adoption Of ‘Ready-to-Use’ Technologies To Be Discussed By Catalent Biologics At The Pharma Forum
Sep 10, 2019
Catalent today announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum, to be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18 – 19, 2019.
Novavax and Catalent Announce Closing of Strategic Partnership
Jul 31, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced the closing of their previously announced arrangement.
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
Jul 16, 2019
Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Catalent’s Partner, Passage Bio, Announces New Dedicated Gene Therapy Manufacturing Suite
Jul 10, 2019
The dedicated cGMP suite is to be built under strategic partnership with Paragon Gene Therapy to support future clinical and commercial production for Passage Bio’s AAV-delivered gene therapies
Catalent’s Partner, Amicus, Announces It Has Entered Into A Strategic Partnership With Catalent For Gene Therapy Development And Manufacturing
Jul 2, 2019
The agreement supports clinical and commercial supply needs for Pompe and other lysosomal disease gene therapy programs
PEGS Europe 2019
Date: November 18-22, 2019
Cell Therapy & Gene Therapy Manufacturing Congress 2019
Date: December 4-6, 2019
DDL 2019
Date: December 11-13, 2019
Webinar | You’ve Got That Coveted Accelerated Regulatory Pathway. Now What?
Date: December 17, 2019
Phacilitate
Date: January 21-24, 2020
CASSS WCBP
Date: January 28-30, 2020
CASSS BIOASSAY
Date: April 26-28, 2020
ISBiotech Spring
Date: March 23-25, 2020
Gene Therapy for Rare Disorders
Date: March 30 – April 2, 2020
BEBPA Bioassay Conference
Date: March 25-27, 2020
World Vaccine Congress
Date: April 7-9, 2020
Interphex
Date: April 28-30, 2020
PEGS Boston
Date: May 4 – 8, 2020
BEBPA HCP
Date: May 13-15, 2020
ISCT 2020
Date: May 27-30, 2020
BIO International Convention
Date: June 8 – 11, 2020